Koers Coeptis Therapeutics, Inc. OTC Markets
Aandelen
COEP
US19207C1045
Farmaceutische producten
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 10,73 mln. 9,94 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -26 mln. -24,09 mln. | Nettowinst (verlies) 2025 * | -35 mln. -32,42 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-0,39
x | K/w-verhouding 2025 * |
-0,34
x | Werknemers | 5 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 61,96% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Mehalick
CEO | Chief Executive Officer | 56 | 28-10-22 |
Brian Cogley
DFI | Director of Finance/CFO | 38 | 17-05-23 |
Daniel Yerace
COO | Chief Operating Officer | 41 | 28-10-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 62 | 28-10-22 | |
Director/Board Member | 55 | 28-10-22 | |
Christine Sheehy
CMP | Compliance Officer | 57 | 28-10-22 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+33,46% | 701 mld. | |
+26,24% | 570 mld. | |
+0,93% | 381 mld. | |
+21,03% | 334 mld. | |
+17,51% | 322 mld. | |
+2,95% | 212 mld. | |
+0,74% | 209 mld. | |
-6,05% | 205 mld. | |
-3,61% | 157 mld. |